MX2022000356A - Compuesto para tratamiento de combinacion. - Google Patents

Compuesto para tratamiento de combinacion.

Info

Publication number
MX2022000356A
MX2022000356A MX2022000356A MX2022000356A MX2022000356A MX 2022000356 A MX2022000356 A MX 2022000356A MX 2022000356 A MX2022000356 A MX 2022000356A MX 2022000356 A MX2022000356 A MX 2022000356A MX 2022000356 A MX2022000356 A MX 2022000356A
Authority
MX
Mexico
Prior art keywords
compound
combination treatment
treatment
combination
anxiety
Prior art date
Application number
MX2022000356A
Other languages
English (en)
Spanish (es)
Inventor
Ulf Simonsen
Simon Comerma-Steffensen
Dan Peters
Original Assignee
Initiator Pharma As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Initiator Pharma As filed Critical Initiator Pharma As
Publication of MX2022000356A publication Critical patent/MX2022000356A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Reproductive Health (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Steroid Compounds (AREA)
MX2022000356A 2019-08-06 2020-08-06 Compuesto para tratamiento de combinacion. MX2022000356A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP19190224 2019-08-06
PCT/EP2020/072092 WO2021023805A1 (en) 2019-08-06 2020-08-06 Compound for combination treatment

Publications (1)

Publication Number Publication Date
MX2022000356A true MX2022000356A (es) 2022-05-11

Family

ID=67551141

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022000356A MX2022000356A (es) 2019-08-06 2020-08-06 Compuesto para tratamiento de combinacion.

Country Status (16)

Country Link
US (1) US20220288052A1 (https=)
EP (2) EP4009942B1 (https=)
JP (1) JP7605825B2 (https=)
KR (1) KR20220054593A (https=)
CN (1) CN114430679A (https=)
AU (1) AU2020326244B2 (https=)
BR (1) BR112022002169A2 (https=)
CA (1) CA3146837A1 (https=)
DK (1) DK4009942T3 (https=)
ES (1) ES2962648T3 (https=)
FI (1) FI4009942T3 (https=)
IL (1) IL290319B2 (https=)
MX (1) MX2022000356A (https=)
PL (1) PL4009942T3 (https=)
WO (1) WO2021023805A1 (https=)
ZA (1) ZA202200723B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4646204A1 (en) * 2023-01-03 2025-11-12 Initiator Pharma A/S Compound for treatment of erectile dysfunction
WO2025051846A1 (en) 2023-09-05 2025-03-13 Initiator Pharma A/S Compound for treatment of female sexual dysfunction

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04012693A (es) * 2002-06-20 2005-03-23 Lundbeck & Co As H Terapia de combinacion en donde se utiliza un inhibidor de recaptacion de serotonina.
RU2354377C2 (ru) * 2003-07-11 2009-05-10 Берингер Ингельхайм Ветмедика Гмбх Способ лечения или предупреждения заболеваний центральной нервной системы с использованием соединений, обладающих селективностью в отношении альфа-3-субъединицы бензодиазепинового рецептора
BRPI0515261A (pt) * 2004-09-30 2008-07-15 Neurosearch As composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, uso do composto quìmico ou de qualquer um de seus isÈmeros ou de qualquer mistura de seus isÈmeros, ou um sal farmaceuticamente aceitável do mesmo, e, método para o tratamento, a prevenção ou o alìvio de uma doença ou de um distúrbio ou de uma condição de um corpo de animal vivo
WO2008074798A1 (en) * 2006-12-20 2008-06-26 Neurosearch A/S Novel chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
BRPI0917802A2 (pt) * 2008-08-21 2016-03-01 Neurosearch As método para tratar um distúrbio de ansiedade, composição farmacêutica, uso do composto, uso de uma combinação, kit de partes, método para tratar, prevenir ou aliviar um distúrbio de ansiedade de um corpo de animal vivo, e, combinação
US20130040985A1 (en) 2010-01-29 2013-02-14 Neurosearch A/S Chromen-2-one derivatives and their use as monoamine neurotransmitter re-uptake inhibitors

Also Published As

Publication number Publication date
WO2021023805A1 (en) 2021-02-11
FI4009942T3 (fi) 2023-09-26
CN114430679A (zh) 2022-05-03
ES2962648T3 (es) 2024-03-20
BR112022002169A2 (pt) 2022-06-07
AU2020326244B2 (en) 2025-06-05
AU2020326244A1 (en) 2022-03-17
IL290319A (en) 2022-04-01
IL290319B2 (en) 2023-06-01
DK4009942T3 (da) 2023-10-23
EP4009942B1 (en) 2023-08-09
EP4009942A1 (en) 2022-06-15
CA3146837A1 (en) 2021-02-11
ZA202200723B (en) 2022-08-31
EP4241839A2 (en) 2023-09-13
JP7605825B2 (ja) 2024-12-24
US20220288052A1 (en) 2022-09-15
JP2022544463A (ja) 2022-10-19
PL4009942T3 (pl) 2024-04-08
EP4241839A3 (en) 2023-11-15
KR20220054593A (ko) 2022-05-03

Similar Documents

Publication Publication Date Title
MX2023009610A (es) Esteroides neuroactivos, y su metodo de uso.
CL2020002277A1 (es) Formas cristalinas de compuesto de triazolopirimidina (divisional 201803734)
MX2023004593A (es) Inhibidores de tirosina cinasa 2 (tyk2) y usos de los mismos.
CL2019001685A1 (es) Composiciones de aminoácidos y métodos para el tratamiento de enfermedades y trastornos musculares.
DOP2019000180A (es) INHIBIDORES DE TGFß1 ISOFORMA-ESPECÍFICOS CONTEXTO-PERMISIVOS Y USO DE LOS MISMOS
SV2018005612A (es) Agentes, usos y metodos para el tratamiento de la sinucleinopatia
CL2019000230A1 (es) Composiciones y métodos de inhibición del masp-3 para el tratamiento de diversas enfermedades y trastornos.
CR20190071A (es) Compuestos, composiciones y métodos para el tratamiento de enfermedades
MX2024000349A (es) Compuestos y usos de los mismos.
CO2022009696A2 (es) Anticuerpo anti-lilrb1 y usos del mismo
UY40872A (es) Compuestos tricíclicos fusionados de piridazinona útiles para tratar infecciones de orthomyxovirus
CO2017008469A2 (es) Anticuerpos anti-transtiretina
CO2019007205A2 (es) Usos terapéuticos de un polvo de insectos
AR115583A1 (es) Composiciones y métodos para el tratamiento de las enfermedades y trastornos del hígado
CL2019001749A1 (es) Uso de anticuerpos anti-esclerostina en el tratamiento de osteogenesis imperfecta.
MX394875B (es) Terapia combinada para trastornos neuropsiquiatricos sensibles al antagonista de nmdar.
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
MX2020004666A (es) Compuestos de pilocarpina con ácido lipoico para el tratamiento de trastornos oculares.
CO2021000087A2 (es) Combinación de factor vii y de un anticuerpo biespecífico dirigido contra los factores ix y x
MX2022000356A (es) Compuesto para tratamiento de combinacion.
MX2017010654A (es) Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estres.
MX2020005952A (es) Uso de mir101 o mir128 en el tratamiento de trastornos convulsivos.
MX2017013879A (es) Composiciones que comprenden anakinra.
CL2019001618A1 (es) Uso de compuestos de carbamato para prevención, alivio o tratamiento del trastorno bipolar.
CL2020002347A1 (es) Nuevo compuesto y composición farmacéutica que lo comprende